nucleoside analogues or interferon
PreclinicalSmall molecule
nucleoside analogues or interferon is one of 36 small molecule programs targeting Hepatitis B. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Emtriva
GileadApproved
Selzentry
GSKApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Cabenuva
GSKApproved
Sunlenca
GileadApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Retrovir
BBp Consulting, Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- WWen-hong Zhang